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Abstract
Background: Immature B lymphocytes and certain B cell lymphomas undergo apoptotic cell death
following activation of the B cell antigen receptor (BCR) signal transduction pathway. Several
biochemical changes occur in response to BCR engagement, including activation of the Syk tyrosine
kinase. Although Syk activation appears to be necessary for some downstream biochemical and
cellular responses, the signaling events that precede Syk activation remain ill defined. In addition,
the requirements for complete activation of the Syk-dependent signaling step remain to be
elucidated.
Results: A mutant form of Syk carrying a combination of a K395A substitution in the kinase
domain and substitutions of three phenylalanines (3F) for the three C-terminal tyrosines was
expressed in a murine B cell lymphoma cell line, BCL1.3B3 to interfere with normal Syk regulation
as a means to examine the Syk activation step in BCR signaling. Introduction of this kinase-inactive
mutant led to the constitutive activation of the endogenous wildtype Syk enzyme in the absence of
receptor engagement through a 'dominant-positive' effect. Under these conditions, Syk kinase
activation occurred in the absence of phosphorylation on Syk tyrosine residues. Although Syk
appears to be required for BCR-induced apoptosis in several systems, no increase in spontaneous
cell death was observed in these cells. Surprisingly, although the endogenous Syk kinase was
enzymatically active, no enhancement in the phosphorylation of cytoplasmic proteins, including
phospholipase Cγ2 (PLCγ2), a direct Syk target, was observed.
Conclusion: These data indicate that activation of Syk kinase enzymatic activity is insufficient for
Syk-dependent signal transduction. This observation suggests that other events are required for
efficient signaling. We speculate that localization of the active enzyme to a receptor complex
specifically assembled for signal transduction may be the missing event.
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Background
The B cell antigen receptor (BCR) is a multi-subunit com-
plex that acts as a key sensor regulating the response of
lymphocytes to their environment (reviewed in [1–7]). In
mature B cells, activation through the BCR stimulates cel-
lular proliferation and differentiation. In immature B
cells, activation through the BCR induces either a state of
unresponsiveness, termed anergy, or death by apoptosis,
depending on the physical nature and concentration of
the antigen [8–25]. In some B cell lymphomas, activation
through the BCR can induce cell cycle arrest and apoptosis
in vitro and tumor dormancy in vivo [19,26–28]. The core
of the multi-subunit BCR is membrane-bound immu-
noglobulin (mIg), which is non-covalently associated
with two co-receptor molecules, CD79a (Igα) and CD79b
(Igβ), products of the mb-1 and B29 genes [29,30]. The bi-
ochemical changes induced by engagement of the BCR are
extensive and include an increase in tyrosine phosphor-
ylation of several intracellular proteins, hydrolysis of
membrane phospholipids, fluxes in the concentration of
intracellular free Ca2+, activation of several serine/threo-
nine kinases including components of the MAP kinase
pathway, and changes in the activities of a panel of tran-
scription factors. Although much is known about the bio-
chemical changes occurring in response to BCR-mediated
activation, the differences in the signal transduction path-
ways that give rise to the different cellular responses fol-
lowing activation of the same receptor in immature versus
mature cells have yet to be elucidated completely (dis-
cussed in detail in refs. [7]).
Some of the earliest changes that occur following BCR en-
gagement are the activation of several non-receptor pro-
tein tyrosine kinases (PTKs), including p55blk (Blk), p59fyn
(Fyn) and p53/56lyn (Lyn) of the Src family [31], Btk of the
Itk/Tec family [32,33] and p72Syk (Syk) of the Syk/ZAP-70
family [34]. The importance of Syk in BCR signaling and
lymphocyte development has been clearly demonstrated
using gene inactivation approaches. Although syk-defi-
cient mice die perinatally, analysis of radiation chimeras
reconstituted with fetal liver from syk-deficient mice has
demonstrated a block in the transition from proB cells to
preB cells, indicating that signal transduction through Syk
is required for early B cell development [35,36]. Inactiva-
tion of the syk gene in the chicken DT40 B cell lymphoma
leads to a loss in the activation of PLCγ2, the increase in
intracellular free Ca2+ and the apoptotic response follow-
ing engagement of the BCR. In contrast, BCR-mediated ac-
tivation of Lyn kinase was largely maintained [37,38]. The
Syk-dependent signaling pathway appears to be facilitated
by the adaptor molecule BLNK (also known as SLP-65 and
BASH) [39–41]. Syk can induce the phosphorylation of
BLNK in co-transfection experiments [42], which may be
important for the recruitment of other Syk substrates like
PLCγ2 through a scaffolding function [42]. BLNK func-
tion is necessary for signal transduction since no Ca2+ flux
or PLCγ2 phosphorylation is observed in response to BCR
engagement in BLNK-deficient DT40 cells [43].
The formation of large protein complexes associated with
the membrane receptor through specific protein-protein
interactions appears to be an early step in BCR-mediated
signal transduction. In response to receptor activation,
Syk becomes non-covalently associated with the BCR
through tandem SH2 domains located in the amino ter-
minal half of the protein [44]. Following engagement of
the BCR, phosphorylation of specific tyrosine residues in
immunoreceptor tyrosine-based activation motifs (ITA-
Ms) found within the cytoplasmic tails of CD79a and
CD79b provides docking sites for Syk localization [45–
47]. The ability of phosphorylated ITAM peptides to selec-
tively enhance Syk kinase activity in vitro suggests that re-
cruitment of Syk to the receptor complex may serve to
activate the kinase, in part, through allosteric changes in
the structure of the Syk protein [44,48,49]. Upon activa-
tion, Syk and the receptor complex become localized in
detergent-resistant cholesterol-rich membrane microdo-
mains (lipid rafts), resulting in the segregation of the BCR
complex from other membrane components [50].
In this report, we describe the use of a mutant form of Syk
that leads to the constitutive activation of the endogenous
wildtype Syk kinase when introduced into B cells – a dom-
inant positive effect – in the absence of detectable tyrosine
phosphorylation. It was anticipated that the presence of a
constitutively active Syk enzyme could help in delineating
the signaling events that occur upstream and downstream
of Syk activation in the BCR signal transduction pathway.
However, although these cells carry a highly active Syk ki-
nase, no evidence for downstream signaling was found.
These data indicate that activation of Syk kinase enzymat-
ic activity in cells is insufficient for signal transduction.
Results
BCR engagement induces apoptosis and Syk activation
Stimulation through the BCR has been shown to induce
changes in cell growth and viability in several B cell sys-
tems, including the human Daudi, chicken DT40 and
mouse WEHI-231 and BCL1.3B3 B cell lymphomas
[12,19,27,38,51–53]. For example, stimulation of
BCL1.3B3 through the BCR suppressed exponential popu-
lation growth in cell culture (Figure 1A). Using flow cy-
tometry to measure membrane permeability and DNA
content of cells, BCR stimulation resulted in a 5-fold in-
crease (6.5 to 32.6%) in the proportion of apoptotic cells
after 24 hrs (Figure 1B).
BCR-mediated tyrosine kinase activation is thought to be
involved in the signal transduction cascades that give rise
to these changes in cell growth and viability [19]. To de-BMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/16
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termine if BCR engagement under these conditions leads
to Syk kinase activation, increasing amounts of anti-IgM
were added to cultured BCL1.3B3 cells. An in vitro Syk spe-
cific immune-complex kinase assay was used to measure
changes in Syk activity in response to BCR stimulation
(Figure 2A). In unstimulated and control treated
BCL1.3B3 cells (lanes 1 and 6), low, basal levels of Syk ac-
tivity were detected. The autophosphorylation activity of
Syk increased dramatically with the addition of anti-IgM;
Syk activity responded in a dose dependent manner and
reached a plateau at 10 µg (lane 4) in which activity was
~15 fold higher than in unstimulated cells.
The kinetics of BCR-induced Syk activation was analyzed
to determine the rates of Syk kinase activation and inacti-
vation following initial engagement of the BCR (Figure
2B). Maximal Syk activation occurred within 1 min of re-
ceptor engagement (lane 3) and decreased to intermediate
levels at times thereafter (lanes 4 and 5). Additional exper-
iments revealed that even 1 hour after BCR stimulation,
Syk activity remained slightly elevated in comparison with
unstimulated cells (data not shown).
The increase in Syk activity in response to BCR engage-
ment in BCL1.3B3 was accompanied by an increase in ty-
rosine phosphorylation of Syk protein in cells (Figure
2C). No phosphorylated tyrosine residues were detected
on Syk in unstimulated or control treated cells (lanes 1,4,
and 5). Tyrosine phosphorylation of Syk peaked after 30
seconds of BCR stimulation (lane 2) and decreased by 5
minutes (lane 3). The rapid induction of tyrosine phos-
phorylation and its subsequent reduction paralleled the
kinetics of Syk kinase activity (Figure 2B).
Expression of a (K395A/3F) mutant Syk results in a domi-
nant positive effect
BCR-mediated apoptosis was preceded by an increase in
Syk kinase activity in BCL1.3B3. Syk has also been impli-
cated in BCR-induced apoptosis found in the chicken B
lymphoma line, DT40 [38]. To determine the role of Syk
kinase activation in the apoptotic response in BCL1.3B3,
overexpression of a mutant form of Syk was used in an ef-
fort to alter the level of Syk activation following BCR en-
gagement. Site-specific mutations were placed in two
regions of Syk. A lysine at amino acid position 395, pre-
dicted to be critical for kinase activity, was replaced by an
alanine (Figure 3A). Three carboxy-terminal tyrosines
(positions 624–6), hypothesized to play regulatory roles,
were replaced by phenylalanines. Based on the effects of
similar mutations in other kinases it was expected that the
combination of these replacements in (K395A/3F)Syk
might produce a dominant negative effect.
BCL1.3B3 cells were infected with defective retroviruses
expressing wildtype or (K395A/3F) mutant Syk. Clones
expressing varying levels of wildtype or mutant Syk mRNA
were identified using a three-primer reverse transcriptase
polymerase chain reaction (RT-PCR) assay (Figure 3B).
Using this approach, PCR products differing in size were
simultaneously amplified from the transgene and the en-
dogenous syk cDNAs in the same PCR reaction. (K395A/
3F)Syk expression varied relative to endogenous Syk and
ranged from undetectable levels (Figure 3C; lanes 8–10)
to equivalent expression levels (lane 4). The highest trans-
gene expression was found in clone 2.1.2.
Figure 1
BCR engagement induces growth arrest associated
with apoptosis in BCL1.3B3  (A) BCL1.3B3 cells were
plated at 1 × 105 cells/ml for 24 hours and then incubated
with 15 µg/ml of rabbit anti-IgM (anti-IgM – closed circle) or
control rabbit anti-ovalbumin (anti-ova – open circle) anti-
body on day 0. Samples were harvested, stained with Trypan
blue and counted on the indicated days. (B) BCL1.3B3 cells
were plated at 2 × 105 cells/ml and incubated with 25 µg of
rabbit anti-IgM antibody or control rabbit anti-ova antibody
for 24 hours. Samples were then harvested, stained with 7-
AAD and Hoechst 33342, and analyzed by flow cytometry. In
the dot plot analysis of 7-AAD (x-axis) and Hoechst (y-axis)
fluorescence, the apoptotic population is circled.
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Figure 2
Syk kinase activation and phosphorylation in response to BCR engagement (A) The immune complex kinase assay
(ICKA) was used to determine Syk activity in BCL1.3B3 cells after incubation with rabbit anti-IgM antibody (0 – 20 µg; lanes 1 –
5) or control rabbit anti-ova antibody (20 µg; lane 6) for 0.5 minutes. Samples were lysed in an NP-40 lysis buffer, Syk was
immunoprecipitated with rabbit anti-Syk-coated protein A agarose beads, and incubated with γ-32P ATP. The immunoprecipi-
tates were resolved by SDS-PAGE and visualized using a phosphorimager. As immunoprecipitation controls, BCL1.3B3 cells
were lysed and samples immunoprecipitated with rabbit α-ova-coated beads (lane 7) or with uncoated beads (lane 8). The
arrowhead marks the migration position of Syk. (B) The kinetics of Syk activation was determined by the (ICKA). Syk was
immunoprecipitated from BCL1.3B3 cells incubated with 15 µg of anti-IgM for 0–10 minutes (lanes 1–5) and analyzed as
described above. As an immunoprecipitation control, cells were stimulated, lysed, and incubated with anti-ova-coated beads
(lane 6). The arrowhead marks the migration position of Syk. (C) Phosphotyrosine levels were determined by anti-phosphoty-
rosine (anti-PY) immunoblotting. BCL1.3B3 cells were unstimulated (lane 1) or stimulated with 15 µg of anti-IgM (lanes 2 and 3)
or anti-ova (lanes 4 and 5) for 0, 0.5, or 5 minutes as indicated. After the cells were lysed, Syk was immunoprecipitated,
resolved by SDS-PAGE under non-reducing conditions, transferred to nitrocellulose, and probed with anti-PY antibody (top
panel). The blot was stripped and reprobed with an anti-Syk antibody (bottom panel). The arrowhead marks the migration
position of Syk.
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Figure 3
Expression of the (K395A/3F)Syk molecule is associated with constitutive Syk kinase activity (A) The amino acid
changes introduced into wildtype Syk to create the (K395A/3F) Syk mutant include the substitution of lysine at amino acid 395
with alanine and the substitution of three tyrosines at amino acid positions 624–6 in the carboxy-terminus with phenylalanines.
(B) The strategy for simultaneously detecting both the (K395A/3F)Syk and endogenous Syk mRNA by RT-PCR involves the use
of three primers. In this case, Primer 3 is complementary to sequences in both the transgene and endogenous syk gene cDNAs,
while Primers 1 and 2 are specific for sequences in the transgene and endogenous syk gene cDNA, respectively. The PCR prod-
ucts produced with Primers 1 and 3 from the transgene cDNA template are larger than the PCR products produced with
Primers 2 and 3 from the endogenous gene cDNA template. The size difference can be assessed following separation by agar-
ose gel electrophoresis. (C) mRNA expression levels of the (K395A/3F)Syk transgene (T) and endogenous (E) Syk gene in
BCL1.3B3 (lane 2), a clone infected with the empty retroviral vector (lane 3), and (K395A/3F)Syk mutant clones (lanes 4–10)
were determined using the RT-PCR strategy described above. All samples were prepared with (+R.T., upper panel) or without
(-R.T., lower panel) reverse transcriptase to control for amplification of contaminating genomic DNA. (D) Syk activity was
evaluated following immunoprecipitation with anti-Syk antibodies from unstimulated (-) or stimulated (+; 15 µg of anti-IgM for
30 seconds) BCL1.3B3 or (K395A/3F)Syk-containing clones (2.1.6, 2.4.2, 2.1.2, and 2.1.7) by the ICKA. Anti-ova was used as an
immunoprecipitation control (C; lanes 3, 6, 9, 12, and 15). (E) BCL1.3B3, cells infected with the MSCV2.1 expression vector
alone (vector control) and (K395A/3F)Syk-infected clones 2.1.2 and 2.1.6, were incubated with or without 15 µg of anti-IgM or
anti-ova for the indicated times and Syk activity evaluated by the ICKA (lanes 1–6). Anti-ova-coated beads were used as an
immunoprecipitation control (C; lane 7). (F) Syk was immunoprecipitated from unstimulated (no antibody (-) or anti-ova (C))
or stimulated (+; 15 µg anti-IgM for 0.5 minutes) BCL1.3B3, a vector control clone, and (K395A/3F)Syk clones 2.1.2 and 2.4.2.
The immunoprecipitates were resolved by SDS-PAGE and evaluated by anti-PY immunoblotting (upper panel). The blot was
stripped and reprobed with an anti-Syk antibody (lower panel). Our data suggests that the binding activity of the antibody used
for immunoprecipitation is partly influenced by the phosphorylation status of Syk; although phosphorylation is not required for
antibody binding, the amount of Syk present in the immunoblot reflects the level of phosphorylation of the protein to some
degree.
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The ICKA was used to determine the effect of (K395A/
3F)Syk expression on endogenous Syk. Syk activity was
measured in parental BCL1.3B3 (Figure 3D, lanes 1–3)
and cells that express the (K395A/3F)Syk molecule (lanes
4 – 15). Surprisingly, cells that expressed the (K395A/
3F)Syk molecule displayed constitutive Syk activity in un-
stimulated cells (lanes 4,7, and 10). A correlation between
constitutive kinase activity and mRNA expression levels of
(K395A/3F)Syk was observed (compare Figure 3C with
Figure 3D); clones with higher levels of (K395A/3F)Syk
mRNA (e.g. clone 2.1.2) had higher levels of constitutive
kinase activity, while clones with lower levels of (K395A/
3F) Syk mRNA (e.g. clones 2.1.6, 2.4.2 and 2.1.7) had
lower levels of constitutive kinase activity. Thus, it ap-
peared that introduction of this mutant form of Syk result-
ed in a dominant positive effect on kinase activity rather
than a dominant negative effect.
To determine if the observed Syk activity is an artefact of
the in vitro assay, a series of immune complex kinase as-
says of Syk precipitated from mixtures of lysates was per-
formed. Most significantly, a mixture of a lysate from
unstimulated BCL1.3B3 cells harbouring wildtype Syk
with a lysate from unstimulated DT40 expressing the
K395A, 3F mutant Syk (see below), at 1:5, 1:1 and 5:1 ra-
tios, showed no activity in the immune complex kinase as-
say (data not shown). These data indicate that the mutant
Syk protein must be expressed together with the wildtype
enzyme in cells to generate the dominant positive pheno-
type, and suggest that it's effect is indirect. Although we
cannot rule out the possibility that the kinase activation is
occurring during the isolation procedure, the results of the
mixing experiment suggest that the wildtype Syk enzyme
is active in vivo under these conditions.
To determine if expression of the (K395A/3F)Syk mutant
resulted in a change in BCR responsiveness, the kinetics of
Syk activation were measured in clones 2.1.2 and 2.1.6
following BCR stimulation (Figure 3E). Incubation with
anti-IgM induced a rapid increase and delayed reduction
in Syk activity with kinetics similar to that of control
clones. Although the basal levels of Syk activity were ele-
vated in clones that expressed the (K395A/3F)Syk mole-
cule, the cells were still responsive to BCR signaling.
To determine if the constitutive Syk activity observed in
unstimulated cells carrying the (K395A/3F) transgene was
accompanied by constitutive Syk tyrosine phosphoryla-
tion, the levels of phosphotyrosine on Syk were deter-
mined by immunoblotting after immunoprecipitation
(Figure 3F). Syk from unstimulated BCL1.3B3 and vector
control clones had undetectable levels of phospho-tyro-
sine (lanes 1,3,4, and 6, upper panel). Syk from unstimu-
lated clones carrying the (K395A/3F) transgene, which
had constitutive Syk activity, also had undetectable levels
of tyrosine phosphorylation (lane 7, 9, 10 and 12, upper
panel). Thus, despite constitutive Syk activity observed in
these infectants, tyrosine phosphorylation did not corre-
late with activity (compare lanes 7 and 10 of Figure 3D
with lanes 10 and 7 of Figure 3F). Syk from all clones an-
alyzed became tyrosine phosphorylated after BCR stimu-
lation (lanes 2, 5, 8 and 11). It was possible that more Syk
in the immunoprecipitate was required for detection by
the anti-phosphotyrosine antibody. However, even when
more protein was present in the immunoprecipitate, little
if any phosphotyrosine was detected in unstimulated cells
(lanes 13 and 15). These results indicate that Syk activa-
tion does not require tyrosine phosphorylation.
Two hypotheses were considered to explain the high level
of Syk autophosphorylation in the ICKA. In unstimulated
clones expressing the (K395A/3F)Syk molecule, the possi-
bility existed that the intense band observed in the ICKA
(Figure 3D lanes 4, 7, and 10) was not due to increased
Syk activity, but rather to the ability of the background
levels of active endogenous Syk to preferentially phospho-
rylate the (K395A/3F)Syk molecule due to possible chang-
es in its three-dimensional structure. If the kinase activity
of Syk was truly higher in cells expressing (K395A/3F)Syk,
enhanced phosphorylation of an exogenous substrate
would also be observed. To examine the ability of Syk
from cells that expressed (K395A/3F)Syk to phosphor-
ylate an exogenous Syk target, c3b-GST was added to the
Syk ICKA (Figure 4, lower panels). The exogenous sub-
strate was phosphorylated by Syk from unstimulated
clones expressing the (K395A/3F)Syk molecule (lane 7
lower panel), demonstrating that the Syk enzyme isolated
from these cells was highly active.
Although activated endogenous Syk was the likely source
of the constitutive Syk activity observed in clones that ex-
pressed the (K395A/3F)Syk molecule, the possibility re-
mained that the activity might originate from the (K395A/
3F)Syk molecule itself. As proof that the (K395A/3F)Syk
molecule was inactive as predicted, (K395A/3F)Syk and
wildtype Syk expression constructs were transfected into
syk-negative DT40 cells, and activity measured by the
ICKA (Figure 5). While wildtype human Syk was capable
of autophosphorylation (lane 2 upper panel), the
(K395A/3F)Syk mutant was not (lanes 3 and 4) demon-
strating that this molecule was kinase-dead. This result in-
dicates that the constitutive Syk activity identified in
BCL1.3B3 clones expressing (K395A/3F)Syk was likely
due to endogenous Syk and not the (K395A/3F)Syk mu-
tant.
Expression of the (K395A/3F)Syk molecule resulted in
constitutive activation of Syk. However, overexpression of
a full-length unmutated Syk might also generate the same
phenotype. To determine if the constitutive phenotypeBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/16
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was a result of the specific mutations introduced or if
overexpression of a full-length Syk molecule was suffi-
cient to give high basal kinase activity, Syk activity was an-
alyzed from BCL1.3B3 cells that expressed a wildtype
human Syk transgene (Figure 6). The levels of wild-type
human Syk expression were determined using the three-
primer RT-PCR assay described earlier (Figure 6A). Shown
are representative clones that expressed low levels or
equivalent levels of human Syk mRNA as compared with
the levels of endogenous Syk mRNA (lanes 3 and 4, upper
panel). The levels of Syk activity in unstimulated cells ex-
pressing wildtype Syk were indistinguishable from the lev-
els in unstimulated controls (Figure 6B, compare lanes
1,4, and 7). None of the clones analyzed contained elevat-
ed constitutive Syk activity in unstimulated cells, demon-
strating that this phenotype requires the presence of the
unique mutations introduced.
Constitutive Syk activity is insufficient for downstream sig-
naling
In syk-deficient DT40 cells, BCR induced apoptosis was
abrogated indicating that Syk was necessary for this cellu-
lar response [38]. Having established cells with constitu-
tive Syk activity, it was now possible to establish if Syk
activation is sufficient for any of the signaling responses.
However, no impact on cell growth in culture was found
in clones with high constitutive Syk activity, nor was the
growth suppressive effect of anti-IgM treatment enhanced
(Figure 7A). Likewise, no significant difference in apopto-
sis was observed between clones with constitutive Syk ac-
tivity and controls (Figure 7B).
Thus, Syk kinase activity alone was insufficient to signal a
cellular response in BCL1.3B3. However, the presence of
Syk kinase activity was still expected to lead to increased
phosphorylation of protein targets in the absence of stim-
ulation through the BCR. To examine this possibility, the
levels of protein phosphotyrosine were evaluated by im-
munoblotting (Figure 7C). Basal levels of phosphotyro-
sine-containing protein were detected in all clones
analyzed (lanes 1,4,7, and 10). However, no increase was
observed in cells with constitutive Syk activity. After stim-
ulation of BCR, many intracellular proteins became high-
ly phosphorylated on tyrosine to equivalent levels in all
clones, regardless of the level of Syk kinase activity (lanes
2, 5, 8 and 11). These data indicate that despite elevated
basal and induced Syk kinase activity in clones carrying
the (K395A/3F)Syk mutant, global phosphorylation of
cellular proteins was not increased.
The anti-phosphotyrosine immunoblot used is a relative-
ly crude measure of Syk kinase activity in vivo. The possi-
bility remained that any specific effects of constitutive Syk
on its downstream targets might be masked by the com-
bined effects of the other tyrosine kinases activated in re-
sponse to BCR signaling. To focus the investigation on
downstream events of Syk activation, the phosphoryla-
tion state of PLCγ2, an authentic, direct downstream tar-
get of Syk [54], was evaluated. No PLCγ2 phosphorylation
Figure 4
Syk isolated from unstimulated (K395A/3F)Syk-
infected clones can phosphorylate an exogenous sub-
strate Syk was immunoprecipitated from an unstimulated (-)
or stimulated (+, 15 µg anti-IgM for 0.5 minutes) vector con-
trol clone and from a clone expressing the (K395A/3F)Syk
molecule (clone 2.1.2). The ICKA was performed with (lanes
3, 4, 7, and 8) and without (lanes 1, 2, 5, and 6) the human
erythrocyte band-GST substrate, c3B. The arrowhead and
arrow mark the migration position of phosphorylated Syk
and phosphorylated c3B, respectively.
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Vector Control 2.1.2
1234 5 67 8
c3B 
66.2 kDa
26.6 kDa
Stimulation + +
++
+ +
++
Figure 5
The (K395A/3F)Syk protein is enzymatically inactive
Wildtype human Syk and (K395A/3F)Syk were transfected
into syk-negative DT40 chicken B lymphoma cells and cloned.
Syk kinase activity was evaluated by ICKA (upper panel) in
extracts prepared from clones. The levels of wildtype human
Syk and the (K395A/3F)Syk protein in the immunoprecipitate
were also evaluated by anti-Syk immunoblotting (lower
panel). Clones 5.1 and 5.2 represent two independent lines
that express the (K395A/3F)Syk protein. The arrowhead
marks the migration position of Syk. It should be noted that
although these data indicate that mutant Syk is expressed in
DT40 cells and that it is enzymatically inactive, expression of
mutant Syk protein in BCL1.3B3 has not been demonstrated
in these experiments.
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was detected in unstimulated clones containing constitu-
tive Syk activity (Figure 7D, lanes 4 and 7, upper panel).
In contrast, PLCγ2 was rapidly and highly phosphorylated
after stimulation of BCR (lanes 5 and 8). As in the total
cellular phosphotyrosine analysis, the levels of phospho-
tyrosine on PLCγ2 were indistinguishable between con-
trol and experimental cell lines.
Discussion
Previous studies have identified apoptosis and cell cycle
arrest as mechanisms of BCR-induced growth arrest in
BCL1.3B3 cells [19]. The studies presented here have dem-
onstrated that stimulation of the BCR resulted in the rapid
and transient activation of the non-receptor tyrosine ki-
nase, Syk. Previous studies have implicated Syk in BCR-in-
duced apoptosis in other cell lines [37,38]. To examine
the putative role of Syk in BCR-induced apoptosis and cell
cycle arrest in BCL1.3B3, we attempted to alter Syk activity
through the expression of mutant forms of Syk. When the
(K395A/3F)Syk mutant was co-expressed with endog-
enous Syk in BCL1.3B3 cells, a constitutive Syk activation
phenotype was observed. The presence of elevated Syk ac-
tivity allowed us to evaluate the role of Syk activation on
the growth and viability of BCL1.3B3, and on other bio-
chemical changes associated with BCR signaling. To our
surprise, no evidence for downstream signaling was found
in cells with high levels of Syk kinase activity.
Two novel observations were obtained from these studies.
First, expression of the (K395A/3F)Syk molecule in
BCL1.3B3 results in constitutive activation of endogenous
Syk. Since (K395A/3F)Syk was enzymatically inactive
when transfected into Syk-deficient DT40 cells, the ob-
served constitutive kinase activity must be derived from
endogenous Syk and not from the (K395A/3F)Syk pro-
tein. Mutant molecules that inhibit the activation or func-
tion of the wildtype counterpart in the same cell have
been defined as dominant-negative molecules. Since
(K395A/3F)Syk has an activating effect on endogenous
wildtype Syk, we propose that (K395A/3F)Syk is a domi-
nant-positive molecule.
It is likely that the replacement of the three carboxy-termi-
nal tyrosine residues with phenylalanine is necessary for
the dominant-positive phenotype. Zeitlmann et al. found
that transfection of a mutant Syk expression construct car-
rying only the 3F alteration into a T cell lines could over-
come the need for TCR occupancy for IL-2 expression in
PMA-treated cells [62]. However, since the mutant Syk
used retained kinase activity, these studies could not dis-
tinguish between a gain-of-function effect versus a domi-
nant-positive effect as found here.
The mechanism by which the (K395A/3F)Syk molecule
activates endogenous Syk is unknown. One hypothesis is
that a negative regulator of Syk is bound and sequestered
by the (K395A/3F)Syk molecule. By sequestering this neg-
ative regulator, expression of the mutant Syk molecules
gives rise to the activation of the endogenous wildtype
protein in the absence of specific stimulation, leading to a
constitutively active Syk phenotype. Several negative regu-
lators of Syk have been reported. BCR-induced interaction
between Cbl and Syk increases the susceptibility of Syk to
proteolysis [55], possibly through enhancement of ubiq-
uitination [56]. Expression of a dominant-negative SHP-1
phosphatase in the mature murine B cell line K46 resulted
in an increase in BCR-induced Syk kinase activity as meas-
ured by C3b phosphorylation in an ICKA and enhanced
BCR-induced Ca2+ fluxes [57]. It remains to be deter-
mined if interference with any of these known regulatory
proteins is responsible for the dominant-positive effect.
The second novel observation, that Syk kinase enzymatic
activity was insufficient for signal transduction, suggests
that multiple biochemical processes may be required for
Figure 6
Overexpression of a wildtype Syk transgene does not
result in constitutive Syk kinase activity (A) Expression
levels of a wildtype Syk transgene (T) were evaluated as
described in Figure 3C, using RNA isolated from BCL1.3B3
(lane 1), a control vector-infected cell line (lane 2), and
wildtype Syk-infected clones (lanes 3 and 4). (B). An ICKA
for Syk immunoprecipitated from unstimulated (-) and stimu-
lated (+; 15 µg anti-IgM for 0.5 minutes) BCL1.3B3 and
wildtype Syk-infected clones (2.4.1 and 2.4.3). The arrow
marks the migration position of Syk. Anti-ova was used as an
immunoprecipitation control (C; lanes 3, 6, and 9).
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the Syk-dependent step of signal transduction. Presently,
it is unclear what biochemical changes, other than enzy-
matic activation, are required. However, in light of the
present model of signaling through the BCR, perhaps ap-
propriate subcellular localization to the BCR protein com-
plex and the ITAMs of CD79b (Igβ) is also required. In
support of this hypothesis, Syk did not co-precipitate with
IgM in (K395A/3F)Syk-containing cells, without stimula-
tion (data not shown). This is not surprising since the ITA-
Ms in CD79, which are proposed to be docking sites for
Figure 7
Signal transduction and induced apoptosis are unchanged in (K395A/3F)Syk-infected cells despite constitutive
Syk kinase activity (A) A vector-infected control (circle) and a (K395A/3F)Syk-infected clone with constitutive Syk activity,
2.1.2 (square), were plated at 1 × 105 cells/ml and 10 µg anti-IgM (closed symbols) or anti-ova (open symbols) added 24 hrs
later on day 0. Samples were harvested on the indicated days, stained with Trypan blue and viable cell counts were determined.
(B) The responses of a vector control clone (upper row) and (K395A/3F)Syk-infected clone 2.1.2 (lower row) to BCR signaling
were analyzed. 2 × 105 cells were incubated with 15 µg of a polyclonal, goat anti-IgM antibody or 15 µg of a species-matched
control antibody (control Ig) for 24 hours. Samples were harvested, stained with 7-AAD and Hoechst 33342, and analyzed by
flow cytometry. In the dot plot analysis of the 7-AAD (x-axis) and Hoechst (y-axis) fluorescence, the apoptotic population is
circled. The results presented are representative of three independent experiments with similar results. (C) Constitutive Syk
activity does not give rise to a detectable increase in intracellular protein tyrosine phosphorylation. Cell lysates were prepared
from unstimulated (no antibody (-) or anti-ova (C)) and stimulated (+; 15 µg anti-IgM for 0.5 minutes) BCL1.3B3, a vector-
infected control, and (K395A/3F)Syk-infected clones 2.1.2 and 2.4.2 and analyzed by anti-PY immunoblotting. (D) PLCγ2 is not
tyrosine phosphorylated in (K395A/3F)Syk-infected clones with constitutive Syk activity. PLCγ2 was immunoprecipitated from
an unstimulated (-) and stimulated (+, 15 µg anti-IgM for 0.5 minutes) vector-infected control clone and (K395A/3F)Syk-
infected clones 2.1.2, and 2.4.2. The immunoprecipitates were resolved by SDS-PAGE and analyzed by anti-PY immunoblotting
(top panel). The blot was stripped and reprobed with an anti-PLCγ2 antibody (bottom panel). Anti-ova was used as an immu-
noprecipitation control (lanes 3, 6, and 9). The arrows mark the migration position of PLCγ2.
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Syk, are unlikely to be phosphorylated in the absence of
BCR stimulation since phosphorylation of these residues
likely requires activation of Src family tyrosine kinases ex-
pressed in B cells. Therefore, despite constitutive Syk ki-
nase activity, the ITAMs in the dominant-positive-
expressing cells remain hypophosphorylated because ki-
nases that are upstream of Syk and/or are Syk independent
are not active in the absence of BCR crosslinking.
This result implies that in addition to enzymatic activa-
tion, localization of Syk to the BCR might be required for
functional signal transduction. There is precedence for
this model. Mutation of tyrosine 130 in Syk to glutamic
acid had two effects. First, the Y130E mutation resulted in
constitutive activity of Syk. Second, molecules with the
Y130E mutations did not co-immunoprecipitate with the
BCR [58]. A second example involves an in vitro model of
histamine release in the Syk-deficient RBL-2H3 cell line
[59]. When tyrosines 519 and 520 were mutated and in-
troduced into Syk-deficient RBL-2H3 cells, these Syk mol-
ecules were capable of phosphorylation of c3b substrate
in an ICKA. However, despite this activity, there was no
high affinity IgE receptor (Fc∈RI)-induced degranulation.
Further analysis demonstrated neither increases in phos-
photyrosine nor phosphorylation of PLCγ2.
Alternatively, the absence of signal transduction in the
presence of Syk activity may be related to its ability to in-
teract with its downstream targets. Within Syk there are
two phosphotyrosine-binding SH2 domains, allowing for
protein-protein interactions. In addition, phosphotyro-
sine residues in Syk would provide additional sites for
protein-protein interactions. Perhaps, further modifica-
tion is necessary to increase its affinity for downstream
binding partners, e.g. BLNK or PLCγ2.
The absence of signaling in the presence of constitutive
enzymatic activity described for Syk in different systems
implies that execution of the Syk-dependent step in this
signaling cascade is a multi-step process. Multiple require-
ments for progression through this step in the signal trans-
duction pathway may serve to integrate the cellular
response to multiple environmental cues. In this case, the
ultimate cellular response to the activation of the BCR sig-
naling pathway is cell death. Each of these required steps
may provide a regulatory site where other signal transduc-
tion pathways could intersect the default response to anti-
genic stimulation giving rise to an altered cellular
outcome.
Conclusions
In summary, here we describe the use of a mutant Syk con-
struct to produce a dominant-positive effect on endog-
enous Syk activation in the absence of BCR engagement.
The presence of a dominant-positive effect under these
conditions suggests that the Syk kinase is kept inactive in
resting cells by an active suppression mechanisms, which
is disrupted by the presence of the (K395A/3F)Syk mu-
tant. The specific target for this dominant-positive effect
remains to be identified. Although the Syk enzyme is ac-
tive under these conditions, it lacks any detectable phos-
phorylation on tyrosine residues. This observation
indicates that the current paradigm that Syk activation re-
sults from tyrosine phosphorylation may be incorrect. Fi-
nally, the presence of a highly active Syk enzyme in cells
was insufficient for downstream signal transduction as ev-
idenced by a lack of change in global tyrosine phosphor-
ylation, phosphorylation of PLC-γ2 or enhanced
spontaneous or induced apoptosis. These data suggest
that the Syk-dependent step in signal transduction re-
quires biochemical changes in addition to enzymatic acti-
vation, perhaps proper localization of the active enzyme
to a signaling receptor complex.
Methods
Cell Culture
The in vitro-adapted BCL1.3B3 cell line was previously se-
lected from the BCL1 mouse B cell lymphoma for growth
in cell culture [60]. BCL1.3B3 cells were grown in RPMI
supplemented with 25 µg/ml gentamycin, 2 mM L-
glutamine, 100 U/ml penicillin, 100 U/ml streptomycin,
non-essential amino acids (0.1 mM each), 1 mM sodium
pyruvate, 55 µM β-mercaptoethanol, and 5 % heat-inacti-
vated fetal calf serum. For BCL1.3B3 infected clones the
medium was supplemented with 1 mg/ml G418. The syk-
negative DT40 chicken B cell line was obtained from T.
Kurosaki and was grown in RPMI supplemented with 2
mM L-glutamine, 55 µM β-mercaptoethanol, 10 % heat-
inactivated fetal calf serum, and 2 % heat-inactivated
chicken serum. For the syk-negative DT40 transfectants the
medium was supplemented with 2 mg/ml hygromycin B
(Calbiochem, San Diego, CA). All culture medium prod-
ucts were from Gibco BRL (Gaithersburg, MD), unless
otherwise specified.
Antibodies
Polyclonal rabbit anti-IgM antibodies were used to signal
BCL1.3B3 through the BCR [27]. Polyclonal rabbit anti-
ovalbumin was used as a negative control for activation
and immunoprecipitation experiments. Both polyclonal
antibody preparations were purified by affinity chroma-
tography on Sepharose-antigen columns [27]. Immuno-
precipitation of Syk protein utilized an affinity purified
rabbit anti-Syk antibody (SC-573, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, unless otherwise specified). Immu-
noblotting for the detection of Syk protein utilized a
rabbit anti-Syk antibody generated against a different
epitope (SC-1077, Santa Cruz Biotechnology). An affinity
purified anti-PLCγ2 antibody (SC406, Santa Cruz Bio-
technology), was used for both immunoprecipitation andBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/16
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immunoblotting. An anti-phosphotyrosine antibody con-
jugated to horseradish peroxidase (SC7020, Santa Cruz
Biotechnology) was used for the detection of phosphoty-
rosine-containing proteins by immunoblotting.
Viable Cell Counts and Apoptosis Determination by Flow 
Cytometry
Cells were plated in 1 ml of growth medium in flat-bot-
tom 24-well plates at a concentration of 2 – 3 × 105 cells/
ml for 24 hr before stimulation with antibodies. All sam-
ples were plated in duplicate unless specified. Cells were
harvested and washed twice with PBS containing 1% fetal
bovine serum. For cell count experiments, viable cells
were enumerated by Trypan Blue exclusion using a hemo-
cytometer (Sigma-Aldrich Inc, St. Louis, MO). For apopto-
sis determinations, cells were resuspended in 50 µl of 400
µM 7-amino actinomycin D (7-AAD) (Molecular Probes,
Inc., Eugene, OR) and incubated for 30 minutes in the
dark on ice. Cells were then simultaneously fixed with the
addition of 830 µl of 0.5% paraformaldehyde in PBS and
stained with the addition of 220 µl of 10 µg/ml Hoechst
33342 (Molecular Probes, Inc.) containing 5% Tween-20
(Sigma-Aldrich, Inc) for at least 16 hours at 4°C in the
dark. Fluorescence data from 1 × 104 cells was collected
using a FACStar™ Plus (Becton Dickinson, San Diego, CA)
and analyzed with CELLQUEST software (Becton Dickin-
son).
Expression constructs
The retroviral vectors and ecotropic packaging cell line,
BOSC23, used were obtained from W. Pear (U. Penn) and
have been described elsewhere [61]. MSCV2.1 and
MSCVhph contain the neomycin and hygromycin resist-
ance genes, respectively. DNA carrying the wildtype syk
coding region was generated by polymerase chain reac-
tion (PCR) using high fidelity polymerase (Perkin Elmer,
Branchburg, NJ) forward-5'gacacctgccgaggtgtgtg3' and re-
verse  5'gagggaggtggctgacaatc3'  primers, and random-
primed cDNA template derived from the human Burkitt's
lymphoma cell line, Daudi. The PCR product was cloned
into the TA cloning vector pCR3 according to the manu-
facturer's protocol (Invitrogen, Carlsbad, CA). pCR3/syk
was used as a template for introduction of the mutations
described in the text using the Transformer Site-Directed
Mutagenesis Kit (Clontech, Palo Alto, CA) according to
manufacturers instructions. Wildtype and mutant syk
DNA fragments were subcloned into the EcoRI site of
MSCV2.1. Wildtype and mutant syk DNA fragments were
further subcloned from MSCV2.1 into MSCVhph follow-
ing digestion with BstEII and HpaI.
Retroviral infections
MSCV/syk expression vectors were packaged into viral
particles by transient transfection of 1 × 106 BOSC cells
with 15 µg of plasmid DNA/CaPO4  precipitates [61].
BCL1.3B3 cells were infected with 500 µl of a 1:2 dilution
of viral supernatant in growth medium containing 4 µg/
ml polybrene (Sigma-Aldrich, Inc.). Stable infectants were
selected in medium supplemented with 1 mg/ml G418
and 15% BCL1.3B3-conditioned medium. Single cell
clones were generated by limiting dilution. syk-negative
DT40 cells were transfected by electroporation at 950
µFarads, 0.25 kV in PBS using an electroporator (BioRad,
Hercules, CA.). Expression vectors conferring hygromycin
resistance and containing wildtype or mutant Syk were
used. Transfectants were selected in RPMI supplemented
with L-glutamine, β-mercaptoethanol and hygromycin B.
Bulk culture syk-negative DT40 transfectants were used in
the specified experiments.
Immune complex kinase assay (ICKA)
3 – 5 × 106 BCL1.3B3 cells and infectants were stimulated
with 15 µg of affinity purified rabbit anti-mouse IgM or
anti-ovalbumin antibody at 37°C for 30 sec (unless other-
wise specified). Stimulated cells were then resuspended in
Lysis Buffer containing 5% nonidet P-40 (NP-40, Sigma-
Aldrich, Inc.). After 15 min, Lysis Buffer was added so that
the final NP40 concentration was 1%. Lysis Buffer con-
tained 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 µg/ml
aprotinin, 10 µg/ml leupeptin, 1 mM EDTA, 50 mM NaF,
and 1 mM Na orthovanadate (all from Sigma-Aldrich,
Inc.). Nuclei were removed by centrifugation at 18,000 ×
g at 4°C. Supernatants were recovered and incubated with
protein-A agarose beads (Gibco BRL) coated with a rabbit
anti-Syk antibody (SC-573, Santa Cruz Biotechnology,
Inc.) for 30 min. The immunoprecipitates were pelleted,
washed three times with wash buffer (1X TBS pH7.5, 0.5
% Triton X 100) and resuspended in Kinase Buffer – 20
mM Tris-HCl pH 7.5, 5 mM MgCl2 and 5 mM MnCl2 (all
from Sigma-Aldrich, Inc.). Samples were then incubated
with 10 µCi [γ-32P]/1.6 pmol ATP (Amersham-Pharmacia
Biotech, Inc., Piscataway, NJ.) for 20 min at room temper-
ature. SDS Sample Buffer was added, and the samples re-
solved by SDS-PAGE (9% polyacrylamide, BioRad) under
reducing conditions unless otherwise specified. The re-
sults were visualized and analyzed using a phosphorimag-
er (Molecular Dynamics, Sunnyvale, CA). Low molecular
weight protein markers (Boehringer Mannheim/Roche
Molecular Biochemicals, Indianapolis, IN) were used as
migration standards. In some experiments, rabbit anti-
mouse IgM was added to control cells during the lysis
step; under these conditions no stimulation of Syk phos-
phorylation or kinase activity was observed.
Immunoprecipitation and immunoblotting
Immunoprecipitates were generated from 2 × 107 cells as
described for the ICKA except that the immunoprecipi-
tates were washed once with PBS and resuspended in SDS
Sample Buffer. 10 µl of immunoprecipitated protein were
loaded per sample. Samples were resolved by SDS-PAGEBMC Immunology 2002, 3 http://www.biomedcentral.com/1471-2172/3/16
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(9% polyacrylamide) and electrophoretically transferred
to nitrocellulose filters (BioRad). For Syk and PLCγ2 de-
tection, filters were blocked with 5% non-fat dry milk
(BioRad). For detection of phosphotyrosine-containing
proteins, filters were blocked with 1% bovine serum albu-
min (Sigma-Aldrich).
List of abbreviations
IgM – immunoglobulin of the M isotype; ova – chicken
ovalbumin; PY – phosphotyrosine; PLCγ2 – phospholi-
pase C γ2; anti – antibody or antiserum generated against
indicated antigen; RT-PCR – reverse transcriptase
polymerase chain reaction; ICKA – immune-complex ki-
nase assay; ITAM – immunoreceptor tyrosine-based acti-
vation motifs; SH2 and SH3 – Src homology domains 2
and 3; PBS – phosphate-buffered saline.
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